FIG 2.
Investigator-assessed progression-free survival in Asian and non-Asian patients with palbociclib dose reductions (intention-to-treat population). Gray line indicates the median progression-free-survival.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.